CLINICAL EFFICACY OF TESTOSTERONE UNDECANOATE IN MALE HYPOGONADISM

Publisher Website
Google Scholar
Abstract
Testosterone undecanoate (Restandol) dissolved in oleic acid, was administered orally to 76 hypogonadal males for 3 consecutive 3-wk periods and the subjective clinical response assessed by a standard interview. Plasma testosterone and testosterone undecanoate levels were determined by radioimmunoassay before the study and after 3, 6 and 9 wk treatment. The treatment was effective in 60 of the 66 patients who completed the trial. Ten patients did not complete the trial; 2 for reasons unrelated to the drug and 8 because of side effects, mainly gastro-intestinal. There was a significant rise in plasma testosterone levels during treatment and a positive correlation between plasma testosterone and testosterone undecanoate levels. Testosterone undecanoate is a potentially valuable drug for the oral treatment of male hypogonadism.